The signaling by IL-22 proceeds through JAK2/STAT3, which is likely to be suppressed by R9-SOCS3-KIR, making R9-SOCS3-KIR a potential candidate for the treatment of AMD. This evidence concerns the gene IL22 and age-related macular degeneration.